1887

Journal of Medical Microbiology logo

Volume 70, Issue 5

Difference in drug susceptibility distribution and clinical characteristics between and lung diseases in Shanghai, China No Access

Abstract

complex (MAC) has been reported as the most common aetiology of lung disease involving nontuberculous mycobacteria.

Antimicrobial susceptibility and clinical characteristics may differ between and .

We aimed to evaluate the differences in antimicrobial susceptibility profiles between two major MAC species ( and ) from patients with pulmonary infections and to provide epidemiologic data with minimum inhibitory concentration (MIC) distributions.

Between January 2019 and May 2020, 45 and 242 . isolates were obtained from Shanghai Pulmonary Hospital. The demographic and clinical characteristics of patients were obtained from their medical records. The MICs of 13 antimicrobials were determined for the MAC isolates using commercial Sensititre SLOWMYCO MIC plates and the broth microdilution method, as recommended by the Clinical and Laboratory Standards Institute (CLSI; Standards M24-A2). MIC and MIC values were derived from the MIC distributions.

had higher resistance rates than for most tested antimicrobials except clarithromycin, ethambutol, and ciprofloxacin. Clarithromycin was the most effective antimicrobial against both the (88.89 %) and (91.32 %) isolates, with no significant difference between the species (=0.601). The MIC of clarithromycin was higher for (32 µg ml) than (8 µg ml). The MIC of rifabutin was more than four times higher for (1 µg ml) than (≤0.25 µg ml). The percentages of patients aged >60 years and patients with sputum, cough, and cavitary lesions were significantly higher than among patients with infection than infections.

The pulmonary disease caused by distinct MAC species had different antimicrobial susceptibility, symptoms, and radiographic findings.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): clinical characteristics , infection , M. avium , M. intracellulare and MIC distributions
Funding
This study was supported by the:
  • This work were funded by Shanghai Pulmonary Hospital Development Discipline Funds.
    • Principle Award Recipient: NotApplicable
© 2021 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001358
2021-05-17
2024-04-25
Loading full text...

Full text loading...

References

  1. Glassroth J. Pulmonary disease due to nontuberculous mycobacteria. Chest 2008; 133:243–251 [View Article][PubMed]
     [Google Scholar]
  2. Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997 2003. Thorax 2007; 62:661–666 [View Article][PubMed]
     [Google Scholar]
  3. Thomson RM, NTMwgaQTC C. NTM working group at Queensland TB Control Centre and Queensland Mycobacterial Reference Laboratory Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010; 16:1576–1583 [View Article][PubMed]
     [Google Scholar]
  4. van Ingen J, Hoefsloot W, Dekhuijzen PN, Boeree MJ, van Soolingen D. The changing pattern of clinical Mycobacterium avium isolation in the Netherlands. Int J Tuberc Lung Dis 2010; 14:1176–1180[PubMed]
     [Google Scholar]
  5. Billinger ME, Olivier KN, Viboud C, de Oca RM, Steiner C et al. Nontuberculous mycobacteria-associated lung disease in hospitalized persons, United States, 1998-2005. Emerg Infect Dis 2009; 15:1562–1569 [View Article][PubMed]
     [Google Scholar]
  6. Wang L, Zhang H, Ruan Y, Chin DP, Xia Y et al. Tuberculosis prevalence in China, 1990-2010; a longitudinal analysis of national survey data. Lancet 2014; 383:2057–2064 [View Article][PubMed]
     [Google Scholar]
  7. Xu H-B, Jiang R-H, Li L. Treatment outcomes for Mycobacterium avium complex: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis 2014; 33:347–358 [View Article][PubMed]
     [Google Scholar]
  8. Marras TK, Daley CL. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin Chest Med 2002; 23:553–567 [View Article][PubMed]
     [Google Scholar]
  9. Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36:13–34 [View Article][PubMed]
     [Google Scholar]
  10. Jarzembowski JA, Young MB. Nontuberculous mycobacterial infections. Arch Pathol Lab Med 2008; 132:1333–1341 [View Article][PubMed]
     [Google Scholar]
  11. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416 [View Article][PubMed]
     [Google Scholar]
  12. Boyle DP, Zembower TR, Reddy S, Qi C. Comparison of clinical features, virulence, and relapse among Mycobacterium avium complex species. Am J Respir Crit Care Med 2015; 191:1310–1317 [View Article][PubMed]
     [Google Scholar]
  13. Rindi L, Garzelli C. Increase in non-tuberculous mycobacteria isolated from humans in Tuscany, Italy, from 2004 to 2014. BMC Infect Dis 2016; 16:44 [View Article][PubMed]
     [Google Scholar]
  14. Namkoong H, Kurashima A, Morimoto K, Hoshino Y, Hasegawa N et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis 2016; 22:1116–1117 [View Article][PubMed]
     [Google Scholar]
  15. Zhang Z, Pang Y, Wang Y, Cohen C, Zhao Y et al. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Int J Antimicrob Agents 2015; 45:491–495 [View Article][PubMed]
     [Google Scholar]
  16. Renvoise A, Bernard C, Veziris N, Galati E, Jarlier V et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare. J Clin Microbiol 2014; 52:4439–4440 [View Article][PubMed]
     [Google Scholar]
  17. van Ingen J, Kohl TA, Kranzer K, Hasse B, Keller PM et al. Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study. Lancet Infect Dis 2017; 17:1033–1041 [View Article][PubMed]
     [Google Scholar]
  18. Diel R, Ringshausen F, Richter E, Welker L, Schmitz J et al. Microbiological and clinical outcomes of treating Non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis. Chest 2017; 152:120–142 [View Article][PubMed]
     [Google Scholar]
  19. Brown-Elliott BA, Nash KA, Wallace RJ. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012; 25:545–582 [View Article][PubMed]
     [Google Scholar]
  20. Brown-Elliott BA, Iakhiaeva E, Griffith DE, Woods GL, Stout JE et al. In vitro activity of amikacin against isolates of Mycobacterium avium complex with proposed MIC breakpoints and finding of a 16S rRNA gene mutation in treated isolates. J Clin Microbiol 2013; 51:3389–3394 [View Article][PubMed]
     [Google Scholar]
  21. Tanaka E, Kimoto T, Tsuyuguchi K, Watanabe I, Matsumoto H et al. Effect of clarithromycin regimen for Mycobacterium avium complex pulmonary disease. Am J Respir Crit Care Med 1999; 160:866–872 [View Article][PubMed]
     [Google Scholar]
  22. Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006; 174:928–934 [View Article][PubMed]
     [Google Scholar]
  23. Kadota T, Matsui H, Hirose T, Suzuki J, Saito M et al. Analysis of drug treatment outcome in clarithromycin-resistant Mycobacterium avium complex lung disease. BMC Infect Dis 2016; 16:31 [View Article][PubMed]
     [Google Scholar]
  24. Zhao Y, Xu S, Wang L, Chin DP, Wang S et al. National survey of drug-resistant tuberculosis in China. N Engl J Med 2012; 366:2161–2170 [View Article][PubMed]
     [Google Scholar]
  25. CLSI Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes, Second Edition. Approved Standard; 2011 pp M24–A2
     [Google Scholar]
  26. Simons S, van Ingen J, Hsueh PR, Van Hung N, Dekhuijzen PN et al. Nontuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg Infect Dis 2011; 17:343–349 [View Article][PubMed]
     [Google Scholar]
  27. Satta G, McHugh TD, Mountford J, Abubakar I, Lipman M. Managing pulmonary nontuberculous mycobacterial infection. time for a patient-centered approach. Ann Am Thorac Soc 2014; 11:117–121 [View Article][PubMed]
     [Google Scholar]
  28. Wallace RJ, Iakhiaeva E, Williams MD, Brown-Elliott BA, Vasireddy S et al. Absence of Mycobacterium intracellulare and presence of Mycobacterium chimaera in household water and biofilm samples of patients in the United States with Mycobacterium avium complex respiratory disease. J Clin Microbiol 2013; 51:1747–1752 [View Article][PubMed]
     [Google Scholar]
  29. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS et al. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M avium complex lung disease. Chest 2012; 142:1482–1488 [View Article][PubMed]
     [Google Scholar]
  30. Boyle DP, Zembower TR, Qi C. Relapse versus reinfection of Mycobacterium avium complex pulmonary disease. patient characteristics and macrolide susceptibility. Ann Am Thorac Soc 2016; 13:1956–1961 [View Article][PubMed]
     [Google Scholar]
  31. Truden S, Zolnir-Dovc M, Sodja E, Starcic Erjavec M. Nationwide analysis of Mycobacterium chimaera and Mycobacterium intracellulare isolates: frequency, clinical importance, and molecular and phenotypic resistance profiles. Infect Genet Evol 2020; 82:104311 [View Article][PubMed]
     [Google Scholar]
  32. Zheng HW, Pang Y, He GX, Song YY, Zhao YL. Comparing the genotype and drug susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China. Biomed Environ Sci 2017; 30:517–525 [View Article][PubMed]
     [Google Scholar]
  33. Cho EH, Huh HJ, Song DJ, Moon SM, Lee SH et al. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens. J Infect Chemother 2018; 24:315–318 [View Article][PubMed]
     [Google Scholar]
  34. Guthertz LS, Damsker B, Bottone EJ, Ford EG, Midura TF et al. Mycobacterium avium and Mycobacterium intracellulare infections in patients with and without AIDS. J Infect Dis 1989; 160:1037–1041 [View Article][PubMed]
     [Google Scholar]
  35. Maurer FP, Pohle P, Kernbach M, Sievert D, Hillemann D et al. Differential drug susceptibility patterns of Mycobacterium chimaera and other members of the Mycobacterium avium-intracellulare complex. Clin Microbiol Infect 2019; 25:379.e1–37379 [View Article][PubMed]
     [Google Scholar]
  36. Schon T, Chryssanthou E. Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints. Int J Infect Dis 2017; 55:122–124 [View Article][PubMed]
     [Google Scholar]
  37. Wei G, Huang M, Wang G, Huo F, Dong L et al. Antimicrobial susceptibility testing and genotyping of Mycobacterium avium isolates of two tertiary tuberculosis designated hospital, China. Infect Genet Evol 2015; 36:141–146 [View Article][PubMed]
     [Google Scholar]
  38. Zhao X, Wang Y, Pang Y. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China. Infect Genet Evol 2014; 27:332–338 [View Article][PubMed]
     [Google Scholar]
  39. Prince DS, Peterson DD, Steiner RM, Gottlieb JE, Scott R et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N Engl J Med 1989; 321:863–868 [View Article][PubMed]
     [Google Scholar]
  40. Han XY, Tarrand JJ, Infante R, Jacobson KL, Truong M. Clinical significance and epidemiologic analyses of Mycobacterium avium and Mycobacterium intracellulare among patients without AIDS. J Clin Microbiol 2005; 43:4407–4412 [View Article][PubMed]
     [Google Scholar]
  41. Koh W-J, Moon SM, Kim S-Y, Woo M-A, Kim S. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur Respir J 2017; 50:1602503 [View Article][PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.001358
Loading
Difference in drug susceptibility distribution and clinical characteristics between Mycobacterium avium and Mycobacterium intracellulare lung diseases in Shanghai, China
J. Med. Microbiol. 70, 001358 (2021); https://doi.org/10.1099/jmm.0.001358
/content/journal/jmm/10.1099/jmm.0.001358
/content/journal/jmm/10.1099/jmm.0.001358
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error